A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

Not Recruiting

Trial ID: NCT00724334


The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.

Official Title

An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis

Stanford Investigator(s)

Jason Gotlib

Professor of Medicine (Hematology)


Inclusion Criteria:

   - Completion of MF-TG101348-001 study

   - Diagnosis of myelofibrosis

   - At least 18 years of age

Exclusion Criteria:

   - Any acute or chronic medical abnormality that may increase the risk associated with
   study participation


drug: SAR302503 (TG101348)

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office

New Trial Alerts

Receive email alerts when trials open to patients.